2021 Antimicrobial Resistance Benchmark
2021
This report from the Access to Medicine Foundation assesses how 17 major pharmaceutical, biotechnology, and generic medicine manufacturing companies are addressing the rise of antimicrobial resistance (AMR). The report evaluates how these companies are limiting antimicrobial resistance (AMR) specifically across measures of research and development, managing antibacterial manufacturing waste, and ensuring appropriate access to antimicrobial medicines and vaccines in 102 low- and middle-income countries. Though several companies are stepping up to tackle AMR, the pace of change is not rapid enough. The report assigns each company a benchmark score and identifies 11 best practices where companies are performing well.
2021 Antimicrobial Resistance Benchmark
Source:
2021 Antimicrobial Resistance Benchmark. Access to Medicine Foundation 2021. https://accesstomedicinefoundation.org/publications/2021-antimicrobial-resistance-benchmark.